Jury Says Stratagene Must Pay Invitrogen $7.8M for Infringing IP | GenomeWeb
This update clarifies that a jury, not the court, said Stratagene should pay the damages. The presiding judge must still weigh in.
 
NEW YORK (GenomeWeb News) — A jury said Stratagene should pay Invitrogen nearly $8 million in damages for infringing its patents, or around four times less than Invitrogen had hoped to win, Stratagene said today.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.